For the full fiscal year 2008, the Company expects revenues to be between $349 million and $353 million, a projected increase over fiscal 2007 of between 14% and 15%. Net income for the full fiscal year 2008 is projected to be between $35.2 million and $36.2 million, and diluted earnings per share are projected to be between $1.06 and $1.09, an increase over fiscal 2007 of approximately 65% after excluding the effects of a $10.8 million non-recurring tax benefit recognized in the prior year.
Investor Conference Call Webcast
Martek will host a conference call and Webcast for investors to review its third quarter results and fiscal 2008 outlook at 4:45 p.m. Eastern Time on Thursday, September 4, 2008. Access to the live audio Webcast is available through Martek's website at http://investors.martek.com. The webcast will be available for replay through the close of business on October 4, 2008.
Sections of this release contain forward-looking statements concerning,
among other things: (1) Martek's expectations regarding future revenue
growth in and customer demand from the infant formula, pregnancy and
nursing, nutritional supplements, animal feeds and food and beverage
markets; (2) its expectations regarding cash flows from operations and
changes in inventory levels during fiscal 2008; (3) its expectations
regarding revenue, gross margin, operating expense and income for the
fourth quarter of and full year fiscal 2008; and (4) its expectations
regarding launches by customers of products containing Martek's
life'sDHA(TM). Furthermore, Martek's operating results are subject to
quarter-to-quarter fluctuations, some of which may be significant. The
|SOURCE Martek Biosciences Corporation|
Copyright©2008 PR Newswire.
All rights reserved